文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

MitraClip 缘对缘技术经导管治疗重度三尖瓣反流

Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique.
PubMed 文献 · Circulation · 2017-03-23

本观察性研究纳入 64 例不适合手术的重度慢性三尖瓣反流(TR)伴心力衰竭症状患者,采用 MitraClip 系统行经导管修复。器械成功植入率 97%,91% 患者 TR 至少降低 1 级,围术期无死亡、心包填塞、卒中、心肌梗死或大血管并发症,院内死亡 3 例(5%)。作者认为该技术在经选择患者中似安全可行,初步疗效分析显示 TR 减少令人鼓舞,可能潜在改善临床结局。

要点

  • 64 例不适合手术的重度 TR 患者行 MitraClip 治疗,器械成功植入率 97%。
  • 91% 患者术后 TR 至少降低 1 级,13% 患者术后 TR 仍为重度。
  • 院内死亡 3 例(5%),围术期无死亡、心包填塞、卒中、心肌梗死或大血管并发症。

核心结论

  • 作者认为,在这组经选择患者中,MitraClip 系统经导管治疗 TR 似安全可行。
  • 初步疗效分析显示 TR 减少令人鼓舞,可能潜在改善临床结局。

研究设计与样本

  • 观察性研究,纳入 64 例连续患者(平均年龄 76.6±10 岁),均因慢性重度 TR 在最佳药物治疗下仍有心力衰竭症状且被认为不适合手术,以同情用药方式接受 MitraClip 治疗。
  • 安全性定义为围术期不良事件(死亡、心肌梗死、卒中或心包填塞),可行性定义为成功植入 1 枚或以上 MitraClip 器械且 TR 至少降低 1 级,于出院前和 30 天后评估。
  • 功能性结局定义为 NYHA 心功能分级和 6 分钟步行距离的变化。

主要发现

  • 功能性 TR 占 88%,22 例患者同期因二尖瓣反流也接受了 MitraClip 治疗。
  • 术前 88% 患者 TR 为重度或极重度;三尖瓣 MitraClip 器械成功植入率为 97%。
  • 术后 91% 患者 TR 至少降低 1 级,其中 4% 从极重度降至重度;13% 患者术后 TR 仍为重度。
  • 有效反流口面积(0.9±0.3 cm² vs 0.4±0.2 cm²;P<0.001)、缩流颈宽度(1.1±0.5 cm vs 0.6±0.3 cm;P=0.001)和反流体积(57.2±12.8 mL/次 vs 30.8±6.9 mL/次;P<0.001)均显著降低。
  • 围术期无死亡、心包填塞、急诊手术、卒中、心肌梗死或大血管并发症;院内死亡 3 例(5%);NYHA 分级显著改善(P<0.001),6 分钟步行距离显著增加(165.9±102.5 m vs 193.5±115.9 m;P=0.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current surgical and medical treatment options for severe tricuspid regurgitation (TR) are limited, and additional interventional approaches are required. In the present observational study, the safety and feasibility of transcatheter repair of chronic severe TR with the MitraClip system were evaluated. In addition, the effects on clinical symptoms were assessed. METHODS: Patients with heart failure symptoms and severe TR on optimal medical treatment were treated with the MitraClip system. Safety, defined as periprocedural adverse events such as death, myocardial infarction, stroke, or cardiac tamponade, and feasibility, defined as successful implantation of 1 or more MitraClip devices and reduction of TR by at least 1 grade, were evaluated before discharge and after 30 days. In addition, functional outcome, defined as changes in New York Heart Assocation class and 6-minute walking distance, were assessed. RESULTS: We included 64 consecutive patients (mean age 76.6±10 years) deemed unsuitable for surgery who underwent MitraClip treatment for chronic, severe TR for compassionate use. Functional TR was present in 88%; in addition, 22 patients were also treated with the MitraClip system for mitral regurgitation as a combined procedure. The degree of TR was severe or massive in 88% of patients before the procedure. The MitraClip device was successfully implanted in the tricuspid valve in 97% of the cases. After the procedure, TR was reduced by at least 1 grade in 91% of the patients, thereof 4% that were reduced from massive to severe. In 13% of patients, TR remained severe after the procedure. Significant reductions in effective regurgitant orifice area (0.9±0.3cm2 versus 0.4±0.2cm2; P<0.001), vena contracta width (1.1±0.5 cm versus 0.6±0.3 cm; P=0.001), and regurgitant volume (57.2±12.8 mL/beat versus 30.8±6.9 mL/beat; P<0.001) were observed. No intraprocedural deaths, cardiac tamponade, emergency surgery, stroke, myocardial infarction, or major vascular complications occurred. Three (5%) in-hospital deaths occurred. New York Heart Association class was significantly improved (P<0.001), and 6-minute walking distance increased significantly (165.9±102.5 m versus 193.5±115.9 m; P=0.007). CONCLUSIONS: Transcatheter treatment of TR with the MitraClip system seems to be safe and feasible in this cohort of preselected patients. Initial efficacy analysis showed encouraging reduction of TR, which may potentially result in improved clinical outcomes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Nickenig G, Kowalski M, Hausleiter J, et al. Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation. 2017. PMID: 28336788. doi:10.1161/CIRCULATIONAHA.116.024848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。